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three or more days. There were 28 tandem transplant col-
lections (8 patients) with an average of 2.9 days of apheresis
collection per patient. 12.5% (n¼1) of our patients had one
day of collection, 50% (n¼4) had two days and 37.5% (n¼3)
had three or more days of apheresis. Plerixafor was ﬁrst
given in 01/2009 and until 07/2010 our patients received the
drug based on insurance approval or as a second line of
therapy after collection failure. Our algorithm was imple-
mented starting 03/2011 and to date for a single transplant
we have had 109 collections (67 patients) with an average of
1.7 days of collection per patient. 64% of patients (n¼43)
collected in one day, 25% (n¼17) collected in two days and
10% (n¼7) collected in three or more days. There were 42
tandem transplant collections (30 patients) with an average
of 1.5 days of apheresis collection per patient. 77% (n¼23) of
our patients collected in one day, 16.7% (n¼5) collected in
two days and 7% (n¼2) collected in three or more days (see
Figures 1 and 2). There is a signiﬁcant difference between the
number of collection days needed for patients that received
G-CSF alone and the collection days needed for patients
evaluated with our algorithm (p<0.001).
Conclusion/Summary: The addition of an algorithm for the
use of plerixafor has signiﬁcantly reduced the number of
collections needed per patient, which in turn reduces cost
and resources.147
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High-dose melphalan followed by autologous hematopoietic
cell transplant (AHCT) can improve long-term outcome of
patients with primary amyloidosis. Historically, it has been
associated with high transplant related mortality (TRM).
However, improvement in patient selection has resulted in
decreased TRM and improved outcomes. The most common
approach, if patients are determined to be eligible, is to
proceed directly to ASCT. However, at our institution,
patients uniformly receive bortezomib-based induction
therapy to obtain best response prior to transplant.
We performed a retrospective analysis to evaluate the
outcomes of AL amyloidosis patients undergoing ASCT at our
institution.
From 6/2007 to 3/2014, 24 patients underwent AHCT,
receiving either melphalan 200mg/m2 or 140mg/m2 as a
single dose. The median age at transplant was 60 years
(range 35 to 72), with 54% male patients. Karnofsky Perfor-
mance Status was 80% or higher in 87% of patients. Only 13%
had known cardiac involvement. All patients had normal
troponin levels and the median NT-pro-BNP 253 (range 62 to
7580). Themajority of patients had either intermediate (21%)
or high (47%) risk co-morbidity index scores. The median
time from diagnosis to transplant was 8.3 months, with the
majority of patients receiving at least 1 line of prior therapy
(92%). For disease response, following induction therapy, 58%
were transplanted in ﬁrst complete response (CR) or partial
response (PR), 8% in second PR, and 33% with refractory
disease. Patients were mobilized with either G-CSF alone
(79%), G-CSF + plerixafor (17%), or G-CSF + cyclophosphamide
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(range 2.86 to 12.3 x 106). No patient died within 100 days of
transplant. The median follow up was 27 months (range 1.5
to 79.8). The median overall survival at 1 year, 3 years, and 5
years was 87%, 77%, and 77%. Relapse free survival at 1 year, 3
years, and 5 years was 78%, 68%, and 68%.
In conclusion, bortezomib-based therapy followed by
ASCT is well tolerated and can be performed with low TRM,
resulting in durable OS and RFS.148
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Background: While various peripheral blood stem cell
(PBSC) mobilization strategies have been employed, gran-
ulocyte-colony stimulating factor (G-CSF) with or without
plerixafor is widely utilized for its efﬁcacy, safety and cost. To
date, the recombinant G-CSF known as tbo-ﬁlgrastim has not
been compared to traditionally used ﬁlgrastim for mobili-
zation of PBSC or for engraftment after autologous stem cell
transplantation (ASCT). Therefore, we sought to compare the
efﬁcacy and cost of tbo-ﬁlgrastim to ﬁlgrastim during
mobilization and engraftment.
Methods: Patients with lymphoma or plasma cell disor-
ders undergoing G-CSF mobilization, with or without
plerixafor, were included in this retrospective chartTable 1
Patient demongraphics and outcomes*, n ¼ 148
Tbo-ﬁlgrastim Filgrastim P
value
Demographics
Age (years) 56.0 (29.0-72.0) 61.5 (21.0-82.0) 0.016
Gender, male 33 (53.2%) 48 (55.8%) 0.867
Diagnosis 0.472
Plasma cell disorders* 41 (66.1%) 62 (72.1%)
Lymphoma Mobilization 21 (33.9%) 24 (27.9%)
Mobilization
G-CSF(n) 62 86
CD34 Day 4 (cells/mL) 10.5 (0.0-88.0) 12.5 (1.0-65.0) 0.534
Plerxiafor use 45 (72.6%) 60 (69.8%) 0.854
CD34 Day 5 (cells/mL) 5.00 (1.0-292.0) 43 (4.0-174.0) 0.087
CD34 collected days* (x
106 cells/kg)
4.61 (0.12-19.83) 3.78 (0.68-16.34) 0.150
Total collection days (x 106
cells/kg)
1.4 1.6 0.010
CD34 infused (x 106 cells/
kg)
5.90 (0.12-19.83) 5.56 (1.69-16.34) 0.470
Engraftment
G-CSF (n) 70 78
CD34* infused (x 106 cell/
kg)
3.62 (2.24-10.84) 361 (1.70-9.78) 0.447
Transfusion*
Packed red blood cells 1.7 1.7 0.866
Plalelets 1.7 1.4 0.113
Ferbrile neutropenia 48 (68.6%) 53 (67.9%) 0.935
Days to WBC engraftmentz 11.5 11.7 0.251
Days to platelet
engraftmentz
17.7 18.5 0.244
Note: G-CSF - granulocyte colony stimulating factor; WBC - white blood cells
*All values are median unless otherwise speciﬁed.
zPlasma cell disorder includes multiple myeloma; Waldenstrom’s macro-
globulinemia; and amyloidosis.
zValue reported as mean.review. Patients receiving a second autologous transplant
or mobilized with chemotherapy were excluded. Tbo-ﬁl-
grastim and ﬁlgrastim were given at a dose of 10 mcg/kg
daily for four days prior to PBSC collection on day 5. The
adjunct use of plerixafor was determined by circulating
CD34+ cells/mL on day 4 of mobilization. Post-transplant,
each agent was given at a dose of 5 mcg/kg daily on day
+7 and continued until neutrophil engraftment. The pri-
mary outcome was total collected CD34+ cells/kg. Sec-
ondary outcomes included total collection days, peripheral
CD34+ cells/mL on day 4 of mobilization, and the adjunc-
tive use of plerixafor. Post-transplant outcomes included
time to neutrophil engraftment, the number of blood
product transfusions required prior to engraftment, and
events of febrile neutropenia. Cost minimization analysis
was also conducted to determine direct cost-savings be-
tween the two G-CSF products.
Results: A total of 148 patients were included in the ﬁnal
analysis. Median patient age was 60 years, 81 (55%) were
male and 86 (58%) received ﬁlgrastim. Patients in the ﬁl-
grastim group had a higher median age compared to those
receiving tbo-ﬁlgrastim (61.5 vs 56 years, p¼0.01). There
were no other statistically signiﬁcant differences in patient
demographics between the two groups. Patients receiving
ﬁlgrastim collected a median of 5.565 x 106 CD34+ cells/kg
compared to a median of 5.9 x 106 CD34+ cells/kg for the
tbo-ﬁlgrastim group (p¼0.47). There were no statistically
signiﬁcant differences in all secondary endpoints except a
mean fewer days of collection in patients receiving tbo-ﬁl-
grastim (1.4 vs 1.6 days, p¼0.01). Patients receiving tbo-ﬁl-
grastim had a mean cost savings of $761.46 per patient
during mobilization and $353.46 per patient during
engraftment.
Conclusions: Tbo-ﬁlgrastim demonstrated similar CD34+
yield as compared to ﬁlgrastim in the setting of PBSC
collection with no difference in secondary efﬁcacy and
safety outcomes. Furthermore, tbo-ﬁlgrastim utilization was
associated with cost savings of approximately $1,115 per
patient.149
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The incidence of venous thromboembolic events (VTE) after
autologous stem cell transplantation is around 5 percent.
However, in this setting the incidence of cerebral venous
sinus thrombosis (CVST) is unknown. Here we describe the
ﬁrst reported case of CVST after autologous stem cell trans-
plantation in the literature. In our patient CVST greatly
increased the morbidity of post-transplant care.
A 62-year-old female underwent autologous stem cell
transplantation for multiple myeloma, and at the time of
transplant was in complete remission. On D+17, she devel-
oped acute encephalopathy. A non-contrast computerized
tomographic (CT) scan of the head revealed a thin focus of
hyper attenuation along the right tentorium. Magnetic
Resonance Imaging/Venography (MRI/MRV) head and brain
revealed a dural sinus thrombosis involving the entire right
transverse, sigmoid sinus and visible portions of right in-
ternal jugular vein, without venous infarct of the brain. CT
